Navigation Links
The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance
Date:2/17/2010

MISSION VIEJO, Calif., Feb. 17 /PRNewswire-FirstCall/ -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, hospice care and assisted living companies, today reported record results for the fourth quarter and full year 2009.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO)

Financial Highlights Include:

  • Total revenue was a record $542.0 million for the year and $146.6 million for the quarter, up 15.5% and 18.3% over the comparable periods in 2008;
  • Same-store skilled mix by revenue increased to 50.8% for 2009 from 50.0% in the prior year;
  • The company's same-store skilled revenue increased by 6.7% for the year, and by 9.3% for the quarter, all notwithstanding the negative impact of Medicare's 1.1% net market basket decrease, which took effect on October 1;
  • Consolidated EBITDAR climbed 19.7% to $86.9 million for the year, with consolidated EBITDAR margins improving by 57 basis points to 16.0%;
  • Consolidated net income for the year climbed 18.1% to $32.5 million; and
  • Adjusted net income for the year was $33.4 million, or $1.60 per diluted share.

Operating Results

Ensign's President and Chief Executive Officer '/>"/>

SOURCE The Ensign Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. The Ensign Group, Inc. to Announce Third Quarter 2007 Financial Results
2. The Ensign Group, Inc. Acquires Assets of Three Previously Leased Facilities
3. The Ensign Group, Inc. Reports Third Quarter 2007 Earnings
4. The Ensign Group, Inc. Announces the Appointment of Covey C. Christensen as President of Its Flagstone Subsidiary
5. The Ensign Group Successfully Graduates Troubled Nursing Home from CMS Special Focus Facility Program
6. The Ensign Group Establishes $50 Million Credit Facility with GE Healthcare Financial Services
7. The Ensign Groups Year-End Conference Call Scheduled for Friday, March 7, 2008
8. The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings
9. The Ensign Group Schedules 2008 First Quarter Earnings Call for Thursday, May 8, 2008
10. The Ensign Group, Inc. Reports First Quarter 2008 Earnings
11. The Ensign Group, Inc. Acquires Utah Skilled Nursing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Mayo Clinic researchers have used next generation genomic analysis ... cancer tumors have similar genetic origins, which may help ... in the journal Cancer Research . , "This ... next generation sequencing in adjacent Gleason patterns in the ... in pathology," says ,John Cheville, M.D., Mayo Clinic pathologist ...
(Date:5/23/2013)... May 23, 2013 Dr. Katherine Ahn ... charitable organization in Orange County, OCCares , will hold ... County. The event details are as follows: , Sunday ... Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 , The ... music by Christian vocalists Charmaine & Jonathan Thulin. There ...
(Date:5/23/2013)... Click here to read the full ... increasingly seeing their success develop through merger and ... according to new research carried out by MaRS , ... has compiled its research into a series of articles ... research have shown the general trend that the success ...
(Date:5/23/2013)... Cheap Concert Tickets announces that Paul McCartney will ... North America. This well known ticket website has slashed ... help McCartney fans see Sir Paul live in concert. ... is also offering the customer appreciation code SAVE for additional ... she is also a huge McCartney fan and plans to ...
(Date:5/23/2013)... (HealthDay News) -- Symptoms of borderline personality disorder ... diagnosis and treatment. But researchers in Canada say ... unique to borderline personality disorder: a tendency to ... "They have difficulty processing facial emotions and will ... said Anthony Ruocco, a clinical neuropsychologist and assistant ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 3
... New Non-Steroidal Skin Treatment to Treat All ... with Steroids, BARRINGTON, Ill., Oct. 19 Steroids have ... abuse. There must be reasons why,people use steroid products on ... largest organ of the human body, and it needs to ...
... 19 Uroplasty, Inc. (Amex:,UPI) announced today that ... Securities and Exchange Commission in anticipation of a ... of its,common stock. Craig-Hallum Capital Group and ... connection with this proposed public offering.,A copy of ...
... Scans, Oct 26 & 27, as Part of Clinical Study., CHICAGO, ... Stage III or Stage IV ... at no charge as part of a clinical trial. ... cancer that tests positive for a protein called human ...
... Holdings, Inc. and its,operating subsidiary, US Oncology, Inc., ... November 8, 2007. A conference call and ... EST, for the company,s bondholders following the distribution ... US Oncology,s management,team will discuss the financial results. ...
... Oct. 18 West Pharmaceutical,Services, Inc. (NYSE: ... announcement that it has decided to discontinue marketing ... to the,Company,s customer, Nektar Therapeutics, Inc. The Company,s ... the Exubera inhalation device for Nektar. "We ...
... cancer patients with the poorest prognosis -- those with a ... may survive longer with a drug that chokes off ... by researchers at Dukes Preston Robert Tisch Brain Tumor Center, ... and a standard chemotherapy agent, may increase the amount of ...
Cached Medicine News:Health News:Steroids Are Abused for Skin, Not Just Muscles 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 3Health News:Brain Screenings Offered to Breast Cancer Patients During Breast Cancer Awareness Month 2Health News:West Pharmaceutical Services Issues Statement on Exubera 2Health News:West Pharmaceutical Services Issues Statement on Exubera 3Health News:West Pharmaceutical Services Issues Statement on Exubera 4Health News:Drug combination might offer hope for patients deadly brain tumors 2
(Date:5/23/2013)... 2013  MedVantx, Inc., the company that has pioneered ... today the Company has completed a major expansion of ... products and the upgrade of its systems to offer ... its specialty home delivery pharmacy in Sioux ... manufacturers, physicians, health systems and payors novel distribution services, ...
(Date:5/23/2013)...  Echo Pharma Acquisition Limited ("Royalty Pharma") announced today ... Threshold from 90 percent to 50 percent of Maximum ... with the terms of the Revised Offer Document issued ... Under the terms of the Increased Offer, Royalty Pharma ... ) for $12.50 per share in cash. The Increased ...
(Date:5/23/2013)... May 23, 2013  PAREXEL International Corporation (NASDAQ: ... presenting at the Jefferies Healthcare Conference in New York.  ... and Chief Financial Officer, will be making a presentation ... on Monday, June 3, 2013. A live ... "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
Breaking Medicine Technology:MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10PAREXEL International To Present At Jefferies Healthcare Conference 2
... 2011 Caliper Life Sciences, Inc. (NASDAQ: ... for life science companies, today announced that Kevin Hrusovsky, President ... BioConference Live event, which was held on October 26, and ... Forum on October 27 held at Harvard Medical School. ...
... Conn., Nov. 7, 2011 Boehringer Ingelheim Pharmaceuticals, Inc. ... a Phase 2b study, SOUND-C2, that showed the combination ... compounds – the protease inhibitor BI 201335 and the ... successful in reducing viral load below the lower limit ...
Cached Medicine Technology:Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 3Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 4Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 5
PG Magnum Ring Curettes, total length 12.6" (32 cm), handle length 7.8" (20 cm), handle diameter 1.12" (3 cm), working distance 4.7" (12 cm), dual-coned, precision sharpened rings....
Karlin XL Magnum Cup Curettes, extra long (XL) curettes, black handles, lightweight, length 13 1/4" (33.7 cm), handle length 8 1/2" (21 cm), handle diameter 1 1/4" (32 cm)....
XL Cervical Curette comes with a bayonet design and satin black handles having instrument length 9.5" (24 cm), working distance4.1" (10.4 cm) and handle width 0.6" (1.5 cm)....
Caspar Curette, 250 mm, 10"....
Medicine Products: